Harmony Biosciences Holdings (HRMY) Share-based Compensation (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Share-based Compensation data on file, last reported at $33.8 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 170.17% year-over-year to $33.8 million; the trailing twelve-month figure through Mar 2026 stood at $33.8 million (up 783.31% YoY), and the FY2025 full-year result was $44.9 million, up 186.72% from the prior year.
• Share-based Compensation slipped to $33.8 million in Q1 2026, from $42.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $59.8 million in Q3 2024 to a low of -$30.0 million in Q4 2024.
• A 5-year average of $14.8 million and a median of $9.2 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation jumped 651.53% in 2024 and plunged 61.97% in 2025, its largest moves.
• Tracing HRMY's Share-based Compensation over 5 years: stood at $6.9 million in 2022, then climbed by 14.67% to $8.0 million in 2023, then sank by 477.44% to -$30.0 million in 2024, then jumped by 241.69% to $42.6 million in 2025, then slipped by 20.64% to $33.8 million in 2026.
• Business Quant data shows HRMY's Share-based Compensation at $33.8 million in Q1 2026, $42.6 million in Q4 2025, and $22.7 million in Q3 2025.